Extended Access to Oral Kidney Medications in Medicare
This bill delays the inclusion of oral-only kidney-related drugs into the Medicare payment system until 2033 or until an intravenous alternative is approved. This means kidney patients will continue to have access to current oral treatments for a longer period, potentially impacting their costs and treatment options.
Key points
Delays Medicare payment changes for oral kidney drugs until 2033.
Kidney patients will maintain current access to oral phosphate-reducing medications.
Aims to ensure treatment continuity until an intravenous alternative is available.
Expired
Citizen Poll